These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34519506)

  • 1. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions.
    Qin Z; Qin L; Feng X; Li Z; Bian J
    J Med Chem; 2021 Sep; 64(18):13191-13211. PubMed ID: 34519506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
    Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
    Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.
    Huang CC; Hsu CM; Chao MW; Hsu KC; Lin TE; Yen SC; Tu HJ; Pan SL
    Protein Sci; 2024 Jun; 33(6):e5004. PubMed ID: 38723164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
    Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
    Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
    ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
    Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
    EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.
    Martín Moyano P; Němec V; Paruch K
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cellular localization of the murine serine/arginine-rich protein kinase CLK2 is regulated by serine 141 autophosphorylation.
    Nayler O; Schnorrer F; Stamm S; Ullrich A
    J Biol Chem; 1998 Dec; 273(51):34341-8. PubMed ID: 9852100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
    Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
    PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.
    Tiek D; Wells CI; Schröder M; Song X; Alamillo-Ferrer C; Goenka A; Iglesia R; Lu M; Hu B; Kwarcinski F; Sintha P; de Silva C; Hossain MA; Picado A; Zuercher W; Zutshi R; Knapp S; Riggins RB; Cheng SY; Drewry DH
    Curr Res Chem Biol; 2023; 3():. PubMed ID: 38009092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
    Kallen J; Bergsdorf C; Arnaud B; Bernhard M; Brichet M; Cobos-Correa A; Elhajouji A; Freuler F; Galimberti I; Guibourdenche C; Haenni S; Holzinger S; Hunziker J; Izaac A; Kaufmann M; Leder L; Martus HJ; von Matt P; Polyakov V; Roethlisberger P; Roma G; Stiefl N; Uteng M; Lerchner A
    ChemMedChem; 2018 Sep; 13(18):1997-2007. PubMed ID: 29985556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
    Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
    Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
    Prak K; Kriston-Vizi J; Chan AW; Luft C; Costa JR; Pengo N; Ketteler R
    Biochemistry; 2016 Jan; 55(3):608-17. PubMed ID: 26701387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
    Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
    PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
    Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
    PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment.
    Zu M; Li C; Fang JS; Lian WW; Liu AL; Zheng LS; Du GH
    Molecules; 2015 Nov; 20(11):19735-47. PubMed ID: 26540031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
    ElHady AK; Abdel-Halim M; Abadi AH; Engel M
    J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.